Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272671 | 0.83 | MEN1 (0.62) | MEN1KMT2AGFERKDM4EMAPT | |
| SCHEMBL7828672 | 0.81 | EGFR (0.66) | MEN1KMT2AGFERKDM4EMAPT | |
| SCHEMBL28051926 | 0.80 | KDM4E (0.58) | MEN1KMT2AGFERKDM4EMAPT | |
| SCHEMBL3306625 | 0.78 | KDM4E (0.59) | MEN1KMT2AGFERKDM4EMAPT | |
| SCHEMBL27967619 | 0.76 | KDM4E (0.52) | MEN1KMT2AGFERKDM4EMAPT | |
| SCHEMBL9263671 | 0.75 | MCL1 (0.61) | MEN1KMT2AKDM4ETSHRMCL1 | |
| SCHEMBL29110691 | 0.74 | MEN1 (0.82) | MEN1KMT2AGFERKDM4EMAPT | |
| SCHEMBL3306629 | 0.74 | KDM4E (0.56) | MEN1KMT2AGFERKDM4EMAPT | |
| SCHEMBL2684951 | 0.74 | KMT2A (0.46) | MEN1KMT2AGFERKDM4EMAPT | |
| SCHEMBL1092586 | 0.74 | KDM4E (0.67) | MEN1KMT2AKDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-6489353-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM DISORDERS | IDUN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| EP-1159291-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6184244-B1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2001000658-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | MEN1 2825/4885KMT2A 4013/4885GFER 2026/4885 |
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | MEN1 2806/4885KMT2A 4023/4885GFER 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.